Samsung Bioepis' infliximab biosimilar Renflexis approved in Korea
Korean regulators have approved a second Samsung Bioepis biosimilar, this time granting the JV rights to sell a version of J&J's Remicade (infliximab).
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs